JHOP Articles

Skip to main content

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Managing Patient Expectations and ADC-Related Side Effects

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Care Team and Patient Resources and Tools for mBC

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Assurance in ADC Therapy for HER2+ or HER2-Low mBC

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

FDA Updates

FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants

FDA Updates

Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia

FDA Updates

Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation

FDA Updates

FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma

FDA Updates

Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma

FDA Updates

Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer

FDA Updates

Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program

Page 32 of 200
Results 311 - 320 of 1993